

Supplemental Table S1. Baseline characteristics of the study populations in ABILITY-2 and TIPES – ITT				
Characteristics	ABILITY-2		TIPES	
	ADA (N=84)	PBO(N=81)	ADA (N=20)	PBO (N=20)
Demographics				
Age, years	42.5 (10.8)	38.5 (12.8)	41.5 (12.8)	44.4 (11.1)
Disease duration, years	7.7 (7.9)	6.6 (6.3)	7.9 (9.3)	6.7 (6.2)
Gender (male), n (%)	36 (42)	39 (48)	9 (45)	12 (60)
Disease Characteristics				
HLA-B27 positive, n (%)	56 (67)	44 (56)	11 (55)	5 (25)
IBD (past/present), n (%)	5 (6)	3 (4)	1 (5)	3 (15)
PGA , 0-100 mm VAS	65.2 (15.2)	66.4 (15.9)	65.8 (18.1)	68.4 (17.4)
Patient global pain, 0-100 mm	64.3 (14.0)	65.6(15.9)	59.6 (21.5)	57.9 (16.4)
PhGA , 100 mm VAS	60.3 (15.5)	57.0 (15.0)	47.8 (11.8)	57.0 (12.6)
ASDAS-CRP 0-10 cm VAS	2.9 (0.8)	3.1 (0.8)	2.9 (1.0)	3.2 (0.9)
BASDAI, 0-10 cm VAS	5.7 (1.7)	5.6 (1.6)	5.5 (2.3)	6.0 (1.4)
BASDAI #1	6.0 (2.1)	5.8 (2.2)	5.7 (2.9)	6.5 (2.0)
BASDAI #2	4.3 (3.1)	4.0 (2.8)	5.0 (3.3)	6.0 (2.9)
BASDAI #3	6.6 (2.0)	6.7 (1.7)	6.3 (2.4)	5.9 (2.2)
BASDAI #4	6.1 (2.4)	5.9 (2.2)	5.6 (2.9)	5.6 (2.2)
BASDAI #5	5.7 (2.6)	5.8 (2.3)	5.9 (3.0)	6.7 (1.9)
BASDAI #6	4.9 (2.8)	5.2 (2.8)	4.1 (3.1)	5.1 (3.3)
BASDAI mean #5, #6	5.3 (2.4)	5.5 (2.3)	5.0 (2.9)	5.9 (2.3)
SJC	6.1 (5.6) ^a	7.3 (8.0) ^a	4.3 (4.2) ^b	2.5 (1.9) ^b
TJC	13.0 (12.8) ^c	13.6 (16.1) ^c	9.4 (8.2) ^d	10.6 (5.9) ^d
Enthesitis (past/present), n (%)	48 (57)	57 (70)	13 (65)	14 (70)
Dactylitis (past/present), n (%)	23 (27)	27 (33)	4 (20)	1 (5)
CRP, mg/l	9.7 (17.7)	10.7 (15.7)	7.8 (13.3)	13.5 (26.4)
Concomitant therapies				
Concomitant NSAIDs, n (%)	57 (68)	65 (80)	13 (65)	14 (70)
Concomitant DMARD, n (%)	38 (45)	41 (51)	14 (70)	11 (55)
Concomitant MTX, n (%)	23 (27)	25 (31)	5 (25)	6 (30)
Concomitant SSZ, n (%)	20 (24)	27 (33)	7 (35)	4 (20)

All values are the mean (SD), unless otherwise specified. [†]2 patients missing. ‡5mg/l is upper limit of normal in both trials. #, number; ITT, Intention to treat; ADA, adalimumab; PBO, placebo; HLA-B27, human leukocyte antigen B27; IBD, Inflammatory Bowel Disease; PGA, patient global assessment; PhGA, physician global assessment; VAS, visual analogue scale; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score based on C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; SJC, swollen joint count; TJC, tender joint count; CRP, C-reactive protein; NSAID, nonsteroidal anti-inflammatory drug; DMARD, disease modifying antirheumatic drug; MTX, methotrexate; SSZ, sulfasalazine. ^aSJC 0-76 joints, ^bSJC 0-66 joints, ^cTJC 0-78 joints, ^dTJC 0-68 joints. For TIPES, patient global pain was derived from the mean of BASDAI #3 and #4.